drugset / Trial / NCT05535023
Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
To learn if SAR444245 given in combination with cemiplimab can help to kill cancer cells in patients with HPV-related oropharynx cancer who are scheduled to have surgery to remove the disease
Timeline
- Start
- 2022-08-24
- Primary completion
- 2023-07-25
- Completion
- 2023-07-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cemiplimab | Monoclonal antibody | — | Intravenous |
| Subject | Pegenzileukin | Protein / enzyme biologic | — | Intravenous |